KR102506612B1 - 내피 기능장애 및 염증 질환의 치료 - Google Patents

내피 기능장애 및 염증 질환의 치료 Download PDF

Info

Publication number
KR102506612B1
KR102506612B1 KR1020227005920A KR20227005920A KR102506612B1 KR 102506612 B1 KR102506612 B1 KR 102506612B1 KR 1020227005920 A KR1020227005920 A KR 1020227005920A KR 20227005920 A KR20227005920 A KR 20227005920A KR 102506612 B1 KR102506612 B1 KR 102506612B1
Authority
KR
South Korea
Prior art keywords
cells
stro
cell
endothelial dysfunction
progeny
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227005920A
Other languages
English (en)
Korean (ko)
Other versions
KR20220029758A (ko
Inventor
웨인 그레고리 킴프톤
사이몬 리브스 베일리
실비우 이테스쿠
피터 고쉬
Original Assignee
메소블라스트, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메소블라스트, 아이엔씨. filed Critical 메소블라스트, 아이엔씨.
Publication of KR20220029758A publication Critical patent/KR20220029758A/ko
Application granted granted Critical
Publication of KR102506612B1 publication Critical patent/KR102506612B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
KR1020227005920A 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료 Active KR102506612B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
US61/736,361 2012-12-12
KR1020217004422A KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004422A Division KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료

Publications (2)

Publication Number Publication Date
KR20220029758A KR20220029758A (ko) 2022-03-08
KR102506612B1 true KR102506612B1 (ko) 2023-03-06

Family

ID=50933585

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227005920A Active KR102506612B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
KR1020217004422A Active KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
KR1020157017531A Active KR102217962B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217004422A Active KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
KR1020157017531A Active KR102217962B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료

Country Status (11)

Country Link
US (2) US20160175360A1 (enExample)
EP (2) EP2931876B1 (enExample)
JP (5) JP6572130B2 (enExample)
KR (3) KR102506612B1 (enExample)
CN (2) CN105358163B (enExample)
AU (4) AU2013360024B2 (enExample)
CA (1) CA2893942C (enExample)
ES (1) ES2742035T3 (enExample)
IL (1) IL239308A0 (enExample)
SG (2) SG10201705061RA (enExample)
WO (1) WO2014089623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014701A1 (en) 2007-12-04 2011-01-20 Proteobioactives Pty Ltd. Protection of Progenitor Cells and Regulation of Their Differentiation
JP6572130B2 (ja) * 2012-12-12 2019-09-04 メソブラスト、インコーポレイテッド 内皮機能不全及び炎症の疾患の治療
JPWO2022114111A1 (enExample) * 2020-11-27 2022-06-02

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
PT1493439E (pt) 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
KR101441026B1 (ko) 2004-09-24 2014-10-01 메소블라스트, 아이엔씨. 증폭된 다능성 간엽 전구세포 자손 및 이의 용도
KR101446634B1 (ko) 2005-04-12 2014-10-16 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리
JP2008544957A (ja) * 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ 間充織幹細胞による腎疾患及び多臓器不全の治療法と間充織幹細胞馴化培地
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
US8124071B2 (en) * 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2227238A2 (en) * 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US20110014701A1 (en) * 2007-12-04 2011-01-20 Proteobioactives Pty Ltd. Protection of Progenitor Cells and Regulation of Their Differentiation
US20110200612A1 (en) * 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
EP2350266B1 (en) * 2008-11-20 2015-07-29 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) * 2010-09-29 2012-04-12 Aidan Research And Consulting, Llc. Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CN103841983B (zh) * 2011-06-03 2018-11-02 麦瑟布莱斯特公司 治疗或预防神经性疾病的方法
KR101786862B1 (ko) * 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
AU2013296611B2 (en) * 2012-08-01 2017-11-23 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
JP6572130B2 (ja) * 2012-12-12 2019-09-04 メソブラスト、インコーポレイテッド 内皮機能不全及び炎症の疾患の治療
ES2697573T3 (es) * 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas

Also Published As

Publication number Publication date
AU2013360024B2 (en) 2019-02-28
HK1210209A1 (en) 2016-04-15
KR102367981B1 (ko) 2022-02-25
CN105358163A (zh) 2016-02-24
AU2019202960B2 (en) 2021-07-29
JP2023030116A (ja) 2023-03-07
EP2931876A1 (en) 2015-10-21
EP2931876B1 (en) 2019-05-29
JP2019214571A (ja) 2019-12-19
CN111840329A (zh) 2020-10-30
JP6572130B2 (ja) 2019-09-04
US20160175360A1 (en) 2016-06-23
CA2893942A1 (en) 2014-06-19
WO2014089623A1 (en) 2014-06-19
AU2024227208A1 (en) 2024-10-31
EP2931876A4 (en) 2016-05-25
JP7201715B2 (ja) 2023-01-10
US20240115618A1 (en) 2024-04-11
JP2021073240A (ja) 2021-05-13
AU2019202960A1 (en) 2019-05-16
JP2024147655A (ja) 2024-10-16
EP3556850A1 (en) 2019-10-23
JP2016504311A (ja) 2016-02-12
JP6829288B2 (ja) 2021-02-10
KR102217962B1 (ko) 2021-02-22
SG11201504340YA (en) 2015-07-30
AU2013360024A1 (en) 2015-07-02
AU2021250848A1 (en) 2021-11-04
CN105358163B (zh) 2020-09-11
CN111840329B (zh) 2024-10-15
SG10201705061RA (en) 2017-07-28
CA2893942C (en) 2023-03-28
KR20220029758A (ko) 2022-03-08
KR20210021104A (ko) 2021-02-24
IL239308A0 (en) 2015-07-30
ES2742035T3 (es) 2020-02-12
KR20150093732A (ko) 2015-08-18

Similar Documents

Publication Publication Date Title
JP6505148B2 (ja) 移植片対宿主病の治療法
US20240115618A1 (en) Treatment of diseases of endothelial dysfunction and inflammation
US10159696B2 (en) Methods for treating obesity and/or metabolic syndrome
HK40014520A (en) Treatment of diseases of endothelial dysfunction and inflammation
HK1210209B (en) Treatment of diseases of endothelial dysfunction and inflammation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220222

Application number text: 1020217004422

Filing date: 20210215

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220511

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221207

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230228

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230302

End annual number: 3

Start annual number: 1

PG1601 Publication of registration